Does insulin resistance drive hepatic VLDL overproduction that raises fasting triglycerides and the TG/HDL ratio?

The dysregulation of lipid metabolism in insulin resistance is a central feature of cardiometabolic risk, driven by specific molecular changes in the liver that manifest as predictable alterations in the fasting lipid profile.

Mechanistic basis of VLDL overproduction

In the setting of insulin resistance, the liver's normal response to insulin—the suppression of Very Low-Density Lipoprotein (VLDL) secretion—is significantly impaired.

• Molecular Drivers: The failure of insulin to suppress nuclear FoxO1 results in the increased expression of microsomal triglyceride transfer protein (MTP), which is critical for the assembly and secretion of VLDL.
• Lipogenesis: Despite generalized resistance, the SREBP-1c pathway (driven by mTORC1) remains sensitive to insulin, stimulating de novo lipogenesis. This increases the internal supply of triglycerides available to load into VLDL particles.
• Secretion Rates: Human kinetic studies using stable isotope tracers demonstrate that while healthy individuals reduce VLDL production by 47–62% in response to insulin, those with insulin resistance show a blunted response (reduction of only ~22%), leading to a constant influx of triglyceride-rich VLDL1 particles into the bloodstream.

Clinical effectiveness of the TG/HDL ratio

The triglyceride-to-HDL (TG/HDL) ratio serves as a robust clinical surrogate for identifying these underlying metabolic shifts.

• Insulin Resistance Correlation: Meta-analyses and large-scale studies consistently show that the TG/HDL ratio correlates strongly with HOMA-IR and gold-standard hyperinsulinemic-euglycemic clamp results. Reported Area Under the Curve (AUC) values for identifying insulin resistance range from 0.69 to 0.81.
• VLDL and Lipid Remodeling: High ratios reflect a metabolic environment where VLDL overproduction is coupled with altered lipoprotein lipase activity and increased CETP (cholesteryl ester transfer protein) activity. These processes enrich HDL with triglycerides, which are then hydrolyzed, leading to lower circulating HDL levels and further elevating the ratio.
• Practical Utility: While exact cutoffs for the ratio vary by ethnicity and age (ranging typically from 1.5 to 3.5), it is highly specific—often exceeding 90% specificity in certain cohorts for detecting metabolic syndrome and insulin dysregulation.

Bottom line

The evidence strongly supports that insulin resistance drives hepatic VLDL overproduction through MTP upregulation and enhanced lipogenesis. The TG/HDL ratio is a scientifically plausible and clinically practical marker for both this VLDL overproduction and systemic insulin resistance.